<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142336</url>
  </required_header>
  <id_info>
    <org_study_id>37373</org_study_id>
    <secondary_id>00183</secondary_id>
    <nct_id>NCT01142336</nct_id>
  </id_info>
  <brief_title>Effects of Simvastatin on Biomarkers</brief_title>
  <acronym>SimBio</acronym>
  <official_title>Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it
      produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to see if a drug called simvastatin (brand name Zocor)
      beneficially affects the level of certain molecules (such as proteins) in the spinal fluid of
      people. The molecules the investigators are measuring are thought to be important in the
      development of Alzheimer's disease (AD), and the investigators are testing whether
      simvastatin can change proteins to a level that is associated with a reduced risk for AD.

      Simvastatin has been approved by the United States Food and Drug Administration (FDA) for the
      treatment of high cholesterol and to reduce the risk of coronary artery disease. It is an
      investigational drug in this study.

      Participants will be randomly assigned to Placebo or Simvastatin. The investigators and the
      participant will be blinded. Randomization will be stratified by age and gender.

      This study is being funded by the National Institute on Aging. The investigators will take
      part in this study at the VA Puget Sound Health Care System.

      This study will last up to 1 year. Participants will be asked to come to the VA in Seattle a
      total of 9 times, 2 of those times will be for lumbar punctures (also known as a spinal tap).

      The investigators would also like to ask a person who knows the participant well (such as a
      spouse, child, sibling, or good friend) some questions about the participant's health,
      memory, mood and behavior, and abilities to do daily tasks at the beginning and the end of
      the study.

      Participants must be cognitively normal, healthy, willing to have a lumbar puncture, and not
      need or take any medications to control cholesterol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Aβ42 in Cerebrospinal Fluid (CSF) at 1 Year</measure>
    <time_frame>1-year change of CSF Aβ42 from baseline</time_frame>
    <description>CSF Aβ42 concentration were measured at baseline and after 1-year intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in CSF Total Tau at 1 Year</measure>
    <time_frame>1-yr change</time_frame>
    <description>CSF total tau was measured at baseline and after 1-year of intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in CSF ptau181 at 1 Year</measure>
    <time_frame>1-year change from baseline</time_frame>
    <description>ptau 181 measured in CSF at baseline and after 1-year intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40mg qHS for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet qHS for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 40mg qHS for 1 year</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tablet qHS for 1 year</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (participants must meet the following criteria)

          -  If female of childbearing potential, must have negative pregnancy test at baseline,
             and all subsequent visits.

          -  Age 45 to 64 years inclusive.

          -  Considered cognitively normal with no evidence of memory or other cognitive
             impairments (MMSE &gt;26, Logical Memory delayed recall &gt; 6, CDR score of 0).

          -  Normal or only mildly elevated cholesterol which does not require drug therapy based
             on National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP-III)
             guidelines.

          -  An LDL level above 70mg/dL.

          -  Hamilton Depression Scale (HAM-D) score &lt; 12.

          -  BMI between 18 - 34 (or exception made by MD).

          -  In good recent general health (i.e., no trauma or infection in the 4 weeks before LP).

          -  On stable dose of non-exclusionary medications for the 4 weeks preceding the LP.

          -  Platelet count &gt;100,000.

        Exclusion Criteria (participants must NOT satisfy any of the following conditions)

          -  Any contraindications to LP, such as spinal deformity, severe disease or infection in
             the LP region, bleeding tendency, anticoagulant or blood-thinning medications.

          -  Taken a statin medication in the past 12 months.

          -  Any clinically significant laboratory abnormalities.

          -  Any neurological disorders: multiple sclerosis, epilepsy, stroke, Parkinson's, other
             degenerative CNS disorders, or neuropathy with radicular involvement.

          -  Acute or chronic major psychiatric disorders: schizophrenia, affective disorders, or
             severe anxiety disorders. (Dysthymia allowed, history of MDD allowed if currently in
             remission)

          -  Unstable or poorly controlled medical problems such as: heart failure, diabetes
             (poorly controlled or insulin dependent), hypertension (BP &gt;160/100), pulmonary
             disease with hypoxia or hypercapnia, significant liver disease or known hepatitis C
             seropositivity, renal failure, treatment for cancer in the past 2 years (other than
             non-melanoma skin cancer) or known HIV positive status.

          -  Use of illegal drugs or alcohol abuse (&gt;2 drinks/day or 10/week) within the past year.

          -  Concurrent participation in another investigational drug study.

          -  Use of any exclusionary medications in the 4 weeks prior to screening:

               -  Drugs which could interact with statins: itraconazole, ketoconazole,
                  erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, amiodarone,
                  cyclosporine, isoniazid, quinidine, or large quantities of grapefruit juice (&gt;1
                  quart daily)

               -  Central nervous system acting medications: antipsychotics, anti-Parkinson's
                  disease medications, anti convulsants, or CNS stimulants

               -  Chronic use of benzodiazepines, sedating antihistamines, or other
                  sedative-hypnotic agents (prn use is allowed as long as it is not within 72 hours
                  of LP or cognitive testing)

               -  Medications affecting coagulation and/or inflammation: coumadin, potent
                  anti-inflammatory medications (hydrocortisone, methotrexate or other potent
                  immune-modulating medications), and anti-HIV medications (Aspirin up to 325
                  mg/day is allowed.)

               -  Lipid-lowering drugs: fibrates or niacin &gt;500mg/day (stable dose of omega-3 is
                  allowed)

          -  Does the subject's family history meet any of the following criteria?

               -  Both parents had/have dementia

               -  On one side of the family, over two consecutive generations three relatives
                  had/have dementia?

               -  One parent had an onset of dementia before age 60?

          -  Does the subject have a major active autoimmune or immunological disorder?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <results_first_submitted>March 28, 2017</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Gail Li</investigator_full_name>
    <investigator_title>Associate Professor, Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Prevention</keyword>
  <keyword>Spinal Fluid</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Statin-naïve middle-aged adults were recruited for this single-site trial (Seattle, WA) from the University of Washington Alzheimer's Disease Research Center Registry or the community through newsletters, websites, educational talks, health fairs, local clinics, and newspaper and magazine advertisements.</recruitment_details>
      <pre_assignment_details>917 people were pre-screened by phone for eligibility, 400 did not respond or declined, 457 did not meet inclusion/exclusion criteria.
60 completed a full screen visit. Of these 60 potential participants, 2 were lost to follow-up after screen, 2 withdrew, 7 screen failed and 49 were enrolled and randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin</title>
          <description>Simvastatin 40mg qHS for 1 year</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 1 tablet qHS for 1 year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo 1 tablet qHS for 1 year</description>
        </group>
        <group group_id="B2">
          <title>Simvastatin</title>
          <description>Simvastatin 40mg qHS for 1 year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="4.9"/>
                    <measurement group_id="B2" value="55.7" spread="4.5"/>
                    <measurement group_id="B3" value="55.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF Aβ42 level</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="515" spread="113"/>
                    <measurement group_id="B2" value="520" spread="114"/>
                    <measurement group_id="B3" value="517" spread="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF total tau level</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="17"/>
                    <measurement group_id="B2" value="38" spread="16"/>
                    <measurement group_id="B3" value="41" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CSF ptau level</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="15"/>
                    <measurement group_id="B2" value="27" spread="10"/>
                    <measurement group_id="B3" value="29" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aβ42 in Cerebrospinal Fluid (CSF) at 1 Year</title>
        <description>CSF Aβ42 concentration were measured at baseline and after 1-year intervention.</description>
        <time_frame>1-year change of CSF Aβ42 from baseline</time_frame>
        <population>In the Placebo group, 1 participant was dropped due to AE and 1 was lost to follow-up.
In the Simvastatin group, 1 participant was dropped due to AE. These 3 participants were not included in the primary analysis per analysis plan.
All these 3 subjects were not included in the primary analysis based on our per protocol analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 tab qHS for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>40mg qHS for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aβ42 in Cerebrospinal Fluid (CSF) at 1 Year</title>
          <description>CSF Aβ42 concentration were measured at baseline and after 1-year intervention.</description>
          <population>In the Placebo group, 1 participant was dropped due to AE and 1 was lost to follow-up.
In the Simvastatin group, 1 participant was dropped due to AE. These 3 participants were not included in the primary analysis per analysis plan.
All these 3 subjects were not included in the primary analysis based on our per protocol analysis plan.</population>
          <units>1-yr change, pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="31"/>
                    <measurement group_id="O2" value="0.5" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.53</p_value>
            <p_value_desc>Threshold for significance: 0.05, adjust for 3 primary outcomes using Holm Correction</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response variable was Aβ42 in CSF at 1 year, and predictor variables were Aβ42 in CSF at baseline, treatment group, age, sex, and APOE e4 allele.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF Total Tau at 1 Year</title>
        <description>CSF total tau was measured at baseline and after 1-year of intervention</description>
        <time_frame>1-yr change</time_frame>
        <population>In the Placebo group, 1 participant was dropped due to AE and 1 was lost to follow-up.
In the Simvastatin group, 1 participant was dropped due to AE. These 3 participants were not included in the primary analysis per analysis plan.
All these 3 subjects were not included in the primary analysis based on our per protocol analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 tablet qHS for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>40mg qHS for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF Total Tau at 1 Year</title>
          <description>CSF total tau was measured at baseline and after 1-year of intervention</description>
          <population>In the Placebo group, 1 participant was dropped due to AE and 1 was lost to follow-up.
In the Simvastatin group, 1 participant was dropped due to AE. These 3 participants were not included in the primary analysis per analysis plan.
All these 3 subjects were not included in the primary analysis based on our per protocol analysis plan.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.9"/>
                    <measurement group_id="O2" value="1.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <p_value_desc>Threshold for significance: 0.05, adjusted for 3 primary outcomes using Holm correction</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response variable was total tau in CSF at 1 year, and predictor were total tau in at baseline, treatment group, age, sex, and APOE e4 allele status</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CSF ptau181 at 1 Year</title>
        <description>ptau 181 measured in CSF at baseline and after 1-year intervention</description>
        <time_frame>1-year change from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 tablet qHS for 1 year</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>Simvastatin 40mg qHS for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CSF ptau181 at 1 Year</title>
          <description>ptau 181 measured in CSF at baseline and after 1-year intervention</description>
          <units>1-yr change (final - baseline), pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="12.9"/>
                    <measurement group_id="O2" value="1.7" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <p_value_desc>Threshold for significance: 0.05, adjusted for 3 primary outcomes using Holm correction.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Response variable was p-tau181 in CSF at 1 year, and predictor were p-tau181 in at baseline, treatment group, age, sex, and APOE e4 allele status</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse event information was collected systematically at phone and in-person safety visits spaced 6 weeks to 3 months apart for the duration of the 1 year study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin</title>
          <description>Simvastatin 40mg qHS for 1 year</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 1 tablet qHS for 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>New or worsening Nausea</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>New or worsening diarrhea</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>New or worsening constipation</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>New or worsening Headache</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>New or worsening insomnia</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated serum glutamic-oxaloacetic transaminase (SGOT)</sub_title>
                <description>SGOT lab reading above normal limits</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Elevated Serum glutamic pyruvic transaminase (SGPT)</sub_title>
                <description>SGPT lab reading above normal limits</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Glucose</sub_title>
                <description>Fasting Blood Glucose lab reading above normal limits</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <description>New or worsening muscle pain</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <description>New or worsening muscle weakness</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Elevated serum creatine phosphokinase (CPK)</sub_title>
                <description>serum CPK lab reading above normal limits</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Memory Problems</sub_title>
                <description>Self-reported new or worsening memory problems</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <description>Self-reported new or worsening depressed mood</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Self-reported new or worsening anxiety</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>New or worsening upper respiratory infection</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size is small and statistical power is limited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ge Li, MD, PhD</name_or_title>
      <organization>University of Washington</organization>
      <phone>(206) 764-2485</phone>
      <email>gli@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

